Comments on: Genzyme Acquires Three Cancer Drugs From Bayer, Enters Seattle Biotech Hub

By: Siemens taps Amazon to create new cloud software | Erik Bowman

Siemens taps Amazon to create new cloud software | Erik Bowman — Wed, 01 Apr 2009 14:08:18 +0000

[...] Genzyme will pay between $75 million and $100 million to purchase the Seattle area factory where Leukine is produced, as part oof a larger deal with Bayer AG, reports Xconomy. [...]

By: Targeted Genetics on the brink; Firefox in Europe and more « Erik Bowman’s Blog

Wed, 01 Apr 2009 11:53:27 +0000

[...] Genzyme will pay between $75 million and $100 million to purchase the Seattle area factory where Leukine is produced, as part oof a larger deal with Bayer AG, reports Xconomy. [...]

By: HEALTHBEAT: Huge chemo dose used in experiment to limit spread of - Minneapolis Star Tribune

Tue, 31 Mar 2009 17:10:00 +0000

[...] Genzyme Acquires Three Cancer Drugs From Bayer, Enters Seattle Biotech – XconomyGenzyme, the world s largest maker of drugs for rare genetic diseases, is making a big move into broader diseases like cancer and multiple sclerosis to continue fuelling its growth. The Cambridge, MA-based biotech company said today it is acquiring [...]

By: Chris Rivera

Chris Rivera — Tue, 31 Mar 2009 17:08:20 +0000

This is wonderful news. Having worked for Genzyme for a big part of my career, I can personally say that it is a great company to have move into the region. Oncology is a big focus for them, and having them establish a presence in one of the leading cancer research communities makes a lot of sense. Hopefully, they will grow over time, and create a lot of new jobs in Seattle.
This really fits well with the WBBA’s strategy to grow life sciences in Washington. Genzyme, along with Amgen, Gilead, Phillips Ultrasound and recently Novo Nordisk, send a strong message about the viability and strength of biotech and biomedical industry in the state. I would like to see a few more “anchor” companies establish roots in Washington!